Ruth E Langley

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. pmc Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
    R E Langley
    MRC Clinical Trials Unit, London, UK
    Br J Cancer 105:1107-13. 2011
  2. pmc Clinical evidence for the use of aspirin in the treatment of cancer
    Ruth E Langley
    MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, UK and
    Ecancermedicalscience 7:297. 2013
  3. pmc Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
    Ruth E Langley
    MRC Clinical Trials Unit, London, UK
    Lancet Oncol 14:306-16. 2013
  4. doi request reprint Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer?
    R E Langley
    MRC Clinical Trials Unit, London, UK
    Clin Oncol (R Coll Radiol) 25:e23-30. 2013
  5. ncbi request reprint Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01
    Ruth E Langley
    Department of Oncology, University College of London, UK
    J Clin Oncol 23:8322-30. 2005
  6. pmc Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer
    Ruth E Langley
    Endocrinology and Metabolic Medicine, Imperial College, London, UK
    BJU Int 102:442-5. 2008
  7. doi request reprint Potential pitfalls in the design and reporting of clinical trials
    Matthew R Sydes
    Cancer Group, Medical Research Council Clinical Trials Unit, London, UK
    Lancet Oncol 11:694-700. 2010
  8. ncbi request reprint Potential biomarker for aspirin use in colorectal cancer therapy
    Ruth E Langley
    MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, UK
    Nat Rev Clin Oncol 10:8-10. 2013
  9. ncbi request reprint Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer
    William H Allum
    Department of Surgery, Royal Marsden National Health Services Foundation Trust, London, UK
    J Clin Oncol 27:5062-7. 2009
  10. ncbi request reprint Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006

Detail Information

Publications12

  1. pmc Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
    R E Langley
    MRC Clinical Trials Unit, London, UK
    Br J Cancer 105:1107-13. 2011
    ....
  2. pmc Clinical evidence for the use of aspirin in the treatment of cancer
    Ruth E Langley
    MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, UK and
    Ecancermedicalscience 7:297. 2013
    ....
  3. pmc Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
    Ruth E Langley
    MRC Clinical Trials Unit, London, UK
    Lancet Oncol 14:306-16. 2013
    ..Use of parenteral oestrogen could avoid the long-term complications associated with LHRHa and the thromboembolic complications associated with oral oestrogen...
  4. doi request reprint Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer?
    R E Langley
    MRC Clinical Trials Unit, London, UK
    Clin Oncol (R Coll Radiol) 25:e23-30. 2013
    ....
  5. ncbi request reprint Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01
    Ruth E Langley
    Department of Oncology, University College of London, UK
    J Clin Oncol 23:8322-30. 2005
    ..To compare the effectiveness and tolerability of epirubicin and paclitaxel (EP) with epirubicin and cyclophosphamide (EC) as first-line chemotherapy for metastatic breast cancer (MBC)...
  6. pmc Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer
    Ruth E Langley
    Endocrinology and Metabolic Medicine, Imperial College, London, UK
    BJU Int 102:442-5. 2008
    ..To assess the hormonal effects of Fem7 (Merck, KGaA, Darmstadt, Germany) 100 microg transdermal oestrogen patches on men undergoing first-line androgen-deprivation therapy for prostate cancer...
  7. doi request reprint Potential pitfalls in the design and reporting of clinical trials
    Matthew R Sydes
    Cancer Group, Medical Research Council Clinical Trials Unit, London, UK
    Lancet Oncol 11:694-700. 2010
    ..The areas covered include: assessing the scientific idea; trial design; size and duration of the trial; analysis; and reporting and presentation...
  8. ncbi request reprint Potential biomarker for aspirin use in colorectal cancer therapy
    Ruth E Langley
    MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, UK
    Nat Rev Clin Oncol 10:8-10. 2013
    ..No effect of aspirin was seen in patients with wild-type PIK3CA. Mutated PIK3CA might be a useful biomarker to select patients who would benefit from adjuvant aspirin therapy...
  9. ncbi request reprint Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer
    William H Allum
    Department of Surgery, Royal Marsden National Health Services Foundation Trust, London, UK
    J Clin Oncol 27:5062-7. 2009
    ..Initial results reported in 2002 demonstrated an advantage for both disease-free and overall survival in the CS group. The analysis has now been updated after a median follow-up of 6 years...
  10. ncbi request reprint Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006
    ..We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer...
  11. ncbi request reprint Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)
    Malcolm D Mason
    Velindre Hospital, Department of Oncology and Palliative Medicine, School of Medicine, Cardiff University, Cardiff, UK
    J Natl Cancer Inst 99:765-76. 2007
    ..Adjuvant bisphosphonate treatment improves outcomes of patients with bone metastasis-negative breast cancer, but the effects of bisphosphonates on bone metastases in prostate cancer are not known...
  12. ncbi request reprint The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton, UK
    Radiother Oncol 83:31-41. 2007
    ..Conformal radiotherapy (CFRT) raises the possibility that radiotherapy doses can be increased and long-term efficacy outcomes improved, with safety an important consideration...